Oxodipine

TargetMol
Product Code: TAR-T68123
Supplier: TargetMol
CodeSizePrice
TAR-T68123-1mg1mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-5mg5mg£213.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-10mg10mg£279.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-25mg25mg£477.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-50mg50mg£625.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-100mg100mg£859.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T68123-500mg500mg£1,653.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
Oxodipine, a dihydropyridine-type calcium antagonist , inhibited KCl-induced aortic contraction in rabbits and reduced cardiac force in less potent rat ventricular test-paper contractions. In rat cultured neonatal ventricular myocytes, Oxodipine reduced L-type Ca currents (I) with an IC of 0.24 uM, and against T-type Ca currents (I) with an IC of 0.41 uM. Oxodipine causes constipation in mice and gingival hyperplasia in dogs.
CAS:
90729-41-2
Molecular Weight:
359.37
Pathway:
Membrane transporter/Ion channel|Metabolism
Purity:
0.9922
SMILES:
O=C(OC)C1=C(NC(=C(C(=O)OCC)C1C=2C=CC=C3OCOC32)C)C
Target:
Calcium Channel

References

Gal?n L, et al. Characteristics of Ca2+ channel blockade by oxodipine and elgodipine in rat cardiomyocytes. Eur J Pharmacol. 1998;357(1):93-105. Tamargo J, et al. Effects of oxodipine on 45Ca movements and contractile responses in vascular smooth muscle. Br J Pharmacol. 1989;97(2):339-346. Egros F, et al. An original intragastric delivery system for oral administration of solid formulations to fully conscious rats: its application to oxodipine studies. Eur J Drug Metab Pharmacokinet. 1991;Spec No 3:71-76. Montastruc P, et al. Effect of oxodipine, a novel dihydropyridine calcium channel blocker, in neurogenic hypertensive dogs. Arch Int Pharmacodyn Ther. 1993;321:57-62. Tejerina T, et al. Effects of oxodipine on isolated rabbit aorta and mesenteric resistance vessels. Eur J Pharmacol. 1992;219(2):279-284.